Skip to main content
. 2018 Oct 11;11:124. doi: 10.1186/s13045-018-0670-9

Table 4.

Baseline characteristics and relation with radiological response of the patients whose samples were analyzed by targeted NGS (n = 89)

Total No. (%) Responders No. (%) Non-responders No. (%) p
Treatment NS
 Anastrozole (Arm A) 41 (46.1) 16 (42.1) 25 (49.0)
 Fulvestrant (Arm B) 48 (53.9) 22 (57.9) 26 (51.0)
 Age, mean (range), years 71.9 (51–92) 72.1 (51–87) 72.0 (53–92) NS
Age NS
  ≤ 70 years 41 (46.1) 14 (36.8) 27 (52.9)
  > 70 years 48 (53.9) 24 (63.2) 24 (41.1)
ECOG PS NS
 0 75 (84.3) 33 (86.8) 42 (82.4)
 1 14 (15.7) 5 (13.2) 9 (17.6)
Hormone replacement therapy NS
 Yes 30 (33.7) 15 (39.5) 15 (29.4)
 No 59 (66.3) 24 (60.5) 35(68.6)
Tumor staging NS
 T2 74 (83.1) 31 (81.6) 43 (84.3)
 T3 11 (12.4) 4 (10.5) 7 (13.7)
 T4 4 (4.5) 3 (7.9) 1 (2.0)
Node staging NS
 N0 66 (63.6) 24 (63.2) 42 (82.4)
 N1 21 (30.9) 13 (34.2) 8 (15.7)
 N2 2 (3.6) 1 (2.6) 1 (2.0)
 N3 0 (1.7) 0 (0.0) 0 (0.0)
Elston-Ellis grade NS
 I 20 (22.5) 7 (18.4) 13 (25.5)
 II 57 (64.0) 26 (68.4) 31 (60.8)
 III 9 (10.1) 2 (5.3) 7 (13.7)
 Unknown 3 (3.4) 3(7.9) 0(0.0)
Histological type NS
 Ductal 55 (61.8) 21 (55.3) 34 (66.7)
 Lobular 30 (33.7) 14 (36.8) 16 (31.4)
 Other 4 (4.5) 3 (7.9) 1 (1.9)
Allred score: ER NS
 4–5 2 (2.2) 2 (5.3) 0 (0.0)
 6 4 (4.5) 3 (7.9) 1 (2.0)
 7 13 (14.6) 5 (13.1) 8 (15.7)
 8 70 (78.7) 28 (73.7) 42 (82.3)
Allred score: PR NS
 0–5 38 (42.7) 14 (36.8) 24 (47.1)
 6 14 (15.7) 9 (23.7) 5 (9.8)
 7 20 (22.5) 7 (18.4) 13 (25.5)
 8 17 (19.1) 8 (21.1) 9 (17.6)
Ki-67 NS
  ≥ 20% 25 (28.1) 9 (23.7) 16 (31.4)
  < 20% 61 (68.5) 28 (73.7) 33 (64.7)
 ND 3 (3.4) 1 (2.6) 2 (3.9)

ECOG Eastern Cooperative Oncology Group, ER estrogen receptor, ND not determined, PR progesterone receptor, PS performance status, NS no significance